Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab MB02
- Development stage
- Approved
- Lead developer
- mAbxience Research
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bevacizumab MB02 is a biosimilar monoclonal antibody to reference bevacizumab (originator: Avastin), developed primarily for the treatment of several cancers. Like Avastin, it inhibits vascular endothelial growth factor (VEGF), thereby preventing VEGF from binding to its receptors on endothelial cells and inhibiting tumor angiogenesis. MB02 exhibits equivalent clinical efficacy, safety, immunogenicity, and pharmacokinetics compared to reference bevacizumab, in both preclinical and clinical studies. The drug is developed by mAbxience and has been approved in the US and EU for multiple oncology indications, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, renal cell carcinoma, certain gynecological cancers, and others[1][2][4][5].
- Brand names
- AlymsysOyavas
- Other names
- bevacizumab-maly
02
Targets
Beyond the preview
Go deeper on bevacizumab MB02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab MB02.